Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a steady recovery in consumer spending during the Spring Festival, with significant increases in payment transactions and retail sales compared to the previous year [4][26] - The report emphasizes the importance of high-quality companies in high-growth sectors driven by emotional consumption themes [7][35] Summary by Sections Industry Dynamics - The Spring Festival saw a robust recovery in social consumption, with payment transactions on New Year's Eve reaching 4.931 billion, a 21.64% increase from the previous year [4][26] - Key regions like Hainan and cities such as Tianjin and Zhenjiang showed strong performance in retail and dining, with Hainan's duty-free shopping amounting to 1.03 billion yuan, up 20.9% year-on-year [4][27] - Domestic travel orders surged by 60%, and outbound travel orders increased by over 180% during the holiday period [4][26] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending companies like Laopai Gold and Chaohongji for their differentiated product offerings [7][35] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, with recommendations for Yonghui Supermarket and Aiyingshi [7][35] - Investment Theme 3: Highlight domestic beauty brands that cater to emotional value and innovative safe ingredients, recommending brands like Maogeping and Proya [7][35] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Meilitiantian Medical Health and Aimeike [7][35] Market Performance - The retail and social service indices reported declines of 1.59% and 0.78% respectively during the week from February 9 to February 13, 2026 [6][15] - The report notes that the education sector saw the highest growth among sub-sectors, while the watch and jewelry sector led the year-to-date performance with an 11.29% increase [6][18] Company Highlights - Laopai Gold reported a significant revenue increase of 250.9% in the first half of FY2025, driven by strong consumer demand and brand expansion [37] - Chaohongji is expected to achieve a net profit growth of 125% to 175% in FY2025, supported by its differentiated product strategy [37] - Maogeping and Proya are highlighted for their strong performance in the beauty sector, with Maogeping achieving a revenue increase of 31.3% in FY2025 [37]

Group 1 - The core point of the article is that the recent US Supreme Court ruling on the $175 billion tariff refund has significant implications for both China and the A-share market, despite the refund being an internal US matter [2][6][28] - The $175 billion in tariffs was primarily collected from imports, including a 10% tariff on Chinese goods, and is now being refunded to US importers [8][10] - The refund will indirectly benefit Chinese companies as US importers, who have been financially strained by tariffs, will use the refunded money to pay off debts to Chinese suppliers and resume orders [12][14][28] Group 2 - The immediate impact on the A-share market is expected to be positive, with a potential "opening red" for A-shares as market sentiment improves following the ruling [40][46] - The ruling is seen as a signal that the previous high tariffs on Chinese goods may not be a permanent state, which could lead to a more favorable environment for Chinese exports [20][48] - Structural opportunities in the A-share market are identified, focusing on five main lines: export-oriented sectors, domestic substitution, strategic resources, domestic consumption, and new energy [51][62][88] Group 3 - Export-oriented sectors, particularly those with high exposure to the US market, are expected to benefit directly from the tariff refunds, with companies like Midea Group and Haier expected to see improved performance [52][72][73] - Domestic substitution and self-sufficiency in sectors like semiconductors and military equipment are highlighted as long-term strategic focuses, with companies like SMIC and AVIC Shenyang Aircraft being key players [53][78][86] - Strategic resources such as rare earths and gold are also expected to see price support due to ongoing global supply chain disruptions, benefiting companies like Northern Rare Earth and Shandong Gold [56][87]

与此同时，曾经的"抗衰明星"超声炮热度锐减过半，玻尿酸则在价格战的泥潭中稳守"顶流"地位。当合 规壁垒与技术迭代加速重塑市场，医美行业的"马太效应"正在以一种近乎残酷的方式上演，而减重与脱 发治疗正成为资本竞逐的下一个新大陆。 再生填充材料狂飙后的断层：463%增长与56%下降的"冰与火" 近日，医美平台美呗发布的《2025医美消费榜》显示，再生填充材料成为"年度MVP"，2025年销售额 同比增长93.40%，成为连续三年狂飙的"热门选手"。 在整个赛道狂奔的同时，各个品牌2025年销售额的增速却出现分化：臻爱塑菲以463%的强势增长排名 第一；艾维岚同比增长78.71%，稳扎稳打；伊妍仕的市场受到挤压，同比下降56%。 每经记者｜陈星 每经编辑｜黄博文 2025年的中国医美市场，在喧嚣中迎来了一个微妙的分水岭。 美呗平台最新数据显示，连续三年狂飙的再生填充材料赛道，在2025年销售额整体增长93.40%的光鲜 之下，还出现了内部断层：爱美客旗下的"臻爱塑菲"以463%的增速强势领跑，而昔日"少女针"王者华 东医药的"伊妍仕"却同比下降56%。 成都高新米兰柏羽医学美容医院皮肤科技术院长、副主任医师陈双瑜表 ...

Market Overview - The medical beauty sector experienced a decline of 1.27% on February 13, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4082.07, down 1.26%, while the Shenzhen Component Index closed at 14100.19, down 1.28% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - Jinbo Biological (920982) closed at 217.52, down 0.45% with a trading volume of 3504.16 and a transaction amount of 76.71 million [1] - Aimeike (300896) closed at 145.24, down 1.10% with a trading volume of 22,600 and a transaction amount of 3.32 billion [1] - Huaxi Biological (688363) closed at 47.25, down 1.42% with a trading volume of 34,500 and a transaction amount of 164 million [1] - *ST Meigu (000615) closed at 3.26, down 1.81% with a trading volume of 111,200 and a transaction amount of 36.89 million [1] Capital Flow - The medical beauty sector saw a net outflow of 55.91 million from main funds, while retail investors contributed a net inflow of 21.01 million [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 3.25 million, retail net inflow of 1.37 million [2] - Jinbo Biological: Main funds net outflow of 10.75 million, retail net outflow of 1.08 million [2] - Huaxi Biological: Main funds net outflow of 13.55 million, retail net inflow of 12.55 million [2] - Aimeike: Main funds net outflow of 39.11 million, retail net inflow of 7.09 million [2]

Recent Events - The arbitration case between the company's subsidiary REGEN and Datoo regarding the agency rights for the AestheFill product is still under review. On January 30, 2026, the Shenzhen International Arbitration Court revoked the previous temporary sales restriction on REGEN, but the final outcome of the case has not yet been announced, which may impact the company's future business layout [2]. Business Development - The company is accelerating its diversification efforts, with the anti-hair loss product Minoxidil having obtained a drug registration certificate and is advancing in market promotion. The bone structure beauty filler product "Gekela" has received positive market feedback. These new products may become future growth points, although specific sales targets have not been publicly disclosed [3]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.865 billion yuan and a net profit attributable to shareholders of 1.093 billion yuan, representing year-on-year declines of 21.49% and 31.05%, respectively. The gross profit margin remains high at 93.36%. The ongoing pressure on performance is attributed to intensified industry competition [4]. Stock and Capital Performance - Recent stock price fluctuations have been significant, with two large block trades occurring on February 3, 2026, at a transaction price of 113 yuan per share, reflecting a discount of 23.43%. On February 5, the stock price increased by 5.09% to 155.87 yuan per share. The flow of funds and changes in institutional holdings may reflect market sentiment [5].

Group 1 - The company, Aimeike, reported that as of February 10, 2026, the number of shareholders reached 62,417 [2]

Core Viewpoint - The Biotech Index (970038) closed at 2196.51 points, up 0.05%, with a trading volume of 15.75 billion yuan and a turnover rate of 1.32% [1] Group 1: Index Performance - On the day, 20 stocks in the Biotech Index rose, with Furuimei leading at a 4.45% increase, while 28 stocks fell, with Aimeike leading the decline at 2.87% [1] - The net outflow of main funds from the Biotech Index constituents totaled 327 million yuan, while retail funds saw a net inflow of 162 million yuan [1] Group 2: Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.73%, latest price of 190.36 yuan, and a market cap of 230.8 billion yuan [1] - Deep Technology (sz000021) with a weight of 5.05%, latest price of 28.69 yuan, and a market cap of 45.09 billion yuan [1] - Tigermed (sz300347) with a weight of 4.85%, latest price of 66.60 yuan, and a market cap of 57.34 billion yuan [1] - Other notable constituents include Changchun High-tech, Kanglong Chemical, and Yuyue Medical, all within the biotech sector [1] Group 3: Fund Flow Details - Detailed fund flow for selected stocks shows: - Kanglong Chemical (300759) had a main fund inflow of 10.6 million yuan, but retail funds saw a net outflow of 87.37 million yuan [2] - Furuimei (300049) experienced a main fund inflow of 63.48 million yuan, while retail funds had a net outflow of 64.28 million yuan [2] - Mindray Medical (300760) had a main fund inflow of 45.80 million yuan, with retail funds also experiencing a net outflow [2]

Investment Rating - The report indicates a positive outlook for the cosmetics and medical beauty sector, with strong performance compared to the market [2][3]. Core Insights - Estee Lauder reported double-digit growth in China, with net sales reaching RMB 29.35 billion, a year-on-year increase of 6%, and profits improving by 127% to RMB 1.12 billion [8][26]. - The Tmall beauty category saw a significant increase of 24% year-on-year in January 2026, indicating strong consumer demand and confidence in the market [8][29]. - The report highlights the government's focus on promoting service consumption, which is expected to drive growth in key sectors, including beauty and personal care [9][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 3.7% from January 30 to February 6, 2026 [3]. - The Shenwan Cosmetics Index increased by 2.8%, outperforming the Shenwan A Index by 4.4 percentage points [3]. Company Highlights - Estee Lauder's sales in mainland China surged by 13% to RMB 6.44 billion, confirming the recovery of international beauty brands in the Chinese market [8][26]. - The report notes that the top-performing stocks in the sector included Betaini (+13.5%), Huaxi Biological (+12.0%), and Beijia Clean (+10.8%) [4]. E-commerce Insights - The report provides data on the performance of domestic brands on platforms like Douyin and Tmall, showing significant growth in GMV for several brands [20]. - For instance, the brand "毛戈平" saw a GMV increase of 298% in December 2025 [21]. Market Trends - The overall retail sales of cosmetics in December 2025 grew by 8.8%, with a total retail sales figure of RMB 465.3 billion for the year, reflecting a steady recovery in consumer spending [22][23]. - The report emphasizes the shift in consumer preferences towards personalized and high-quality products, indicating a strategic opportunity for brands to innovate [10][11].

Core Viewpoint - The article discusses the challenges faced by Hai Jiayi Medical, highlighting the decline in stock price despite revenue growth, and the shift in the healthcare service model from expansion through acquisitions to a focus on technological innovation [4][10][31]. Group 1: Company Overview - Hai Jiayi Medical is a leading private medical group in China, primarily focused on oncology services, operating a network of chain hospitals [10][16]. - The company has expanded its operations through acquisitions and partnerships, establishing a presence in various provinces, primarily targeting patients underserved by major hospitals in first-tier cities [16][22]. Group 2: Financial Performance - Despite projected revenue growth to a historical high in 2024, the company's stock price continues to decline, indicating a disconnect between revenue and market valuation [6][20]. - The revenue composition for 2024 shows approximately 45% from oncology services and 55% from non-oncology services, reflecting a diversified income stream [17]. Group 3: Market Dynamics - The healthcare market has shifted post-2020, with a decrease in patient demand and increased supply leading to a challenging business environment for private healthcare providers [20][31]. - Policy changes, particularly stricter medical insurance cost controls, have significantly impacted profitability, with a notable decline in gross margins from high-cost oncology services [23][25]. Group 4: Demand and Supply Factors - The demand for oncology services has weakened, with patients showing reduced willingness to pay for high-cost treatments amid economic pressures, leading to stagnant patient visits and declining revenue growth [28][30]. - Increased competition from public hospitals and other private entities has pressured pricing and profitability, with some acquisitions yielding lower net profit margins than initially expected [30][31]. Group 5: Future Outlook - The article suggests that the traditional model of growth through acquisitions in the healthcare sector may be reaching its limits, with future success likely hinging on technological advancements rather than mere expansion [31].

Group 1 - The medical beauty sector increased by 1.6% compared to the previous trading day, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4123.09, up 1.41%, while the Shenzhen Component Index closed at 14208.44, up 2.17% [1] - The net inflow of main funds into the medical beauty sector was 16.88 million, while retail investors saw a net outflow of 22.37 million [1] Group 2 - The net inflow from speculative funds was 5.49 million, indicating interest from short-term investors [1] - A detailed table of individual stock fund flows in the medical beauty sector was provided, highlighting specific movements [1]